Literature DB >> 28552348

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Abigail E Overacre-Delgoffe1, Maria Chikina2, Rebekah E Dadey3, Hiroshi Yano3, Erin A Brunazzi3, Gulidanna Shayan4, William Horne5, Jessica M Moskovitz6, Jay K Kolls7, Cindy Sander8, Yongli Shuai9, Daniel P Normolle9, John M Kirkwood10, Robert L Ferris11, Greg M Delgoffe12, Tullia C Bruno13, Creg J Workman1, Dario A A Vignali14.   

Abstract

Regulatory T cells (Tregs) are a barrier to anti-tumor immunity. Neuropilin-1 (Nrp1) is required to maintain intratumoral Treg stability and function but is dispensable for peripheral immune tolerance. Treg-restricted Nrp1 deletion results in profound tumor resistance due to Treg functional fragility. Thus, identifying the basis for Nrp1 dependency and the key drivers of Treg fragility could help to improve immunotherapy for human cancer. We show that a high percentage of intratumoral NRP1+ Tregs correlates with poor prognosis in melanoma and head and neck squamous cell carcinoma. Using a mouse model of melanoma where Nrp1-deficient (Nrp1-/-) and wild-type (Nrp1+/+) Tregs can be assessed in a competitive environment, we find that a high proportion of intratumoral Nrp1-/- Tregs produce interferon-γ (IFNγ), which drives the fragility of surrounding wild-type Tregs, boosts anti-tumor immunity, and facilitates tumor clearance. We also show that IFNγ-induced Treg fragility is required for response to anti-PD1, suggesting that cancer therapies promoting Treg fragility may be efficacious.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PD-1; cancer immunotherapy; interferon-γ; interferon-γ receptor; neuropilin-1; regulatory T cells; tumor immunology; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28552348      PMCID: PMC5509332          DOI: 10.1016/j.cell.2017.05.005

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  64 in total

1.  In vivo Treg suppression assays.

Authors:  Creg J Workman; Lauren W Collison; Maria Bettini; Meenu R Pillai; Jerold E Rehg; Dario A A Vignali
Journal:  Methods Mol Biol       Date:  2011

2.  B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.

Authors:  Susan A Olalekan; Yanxia Cao; Keith M Hamel; Alison Finnegan
Journal:  Eur J Immunol       Date:  2015-02-11       Impact factor: 5.532

Review 3.  X-inactivation, imprinting, and long noncoding RNAs in health and disease.

Authors:  Jeannie T Lee; Marisa S Bartolomei
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

Review 4.  Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Authors:  Joannes F M Jacobs; Stefan Nierkens; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

Review 5.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

Authors:  Madhav D Sharma; Lei Huang; Jeong-Hyeon Choi; Eun-Joon Lee; James M Wilson; Henrique Lemos; Fan Pan; Bruce R Blazar; Drew M Pardoll; Andrew L Mellor; Huidong Shi; David H Munn
Journal:  Immunity       Date:  2013-05-16       Impact factor: 31.745

8.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Camera: a competitive gene set test accounting for inter-gene correlation.

Authors:  Di Wu; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2012-05-25       Impact factor: 16.971

10.  Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals.

Authors:  Alexis Battle; Sara Mostafavi; Xiaowei Zhu; James B Potash; Myrna M Weissman; Courtney McCormick; Christian D Haudenschild; Kenneth B Beckman; Jianxin Shi; Rui Mei; Alexander E Urban; Stephen B Montgomery; Douglas F Levinson; Daphne Koller
Journal:  Genome Res       Date:  2013-10-03       Impact factor: 9.043

View more
  184 in total

Review 1.  The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Authors:  Arabella Young; Zoe Quandt; Jeffrey A Bluestone
Journal:  Cancer Immunol Res       Date:  2018-12       Impact factor: 11.151

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Unlocking the Complexities of Tumor-Associated Regulatory T Cells.

Authors:  Jaime L Chao; Peter A Savage
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 4.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

5.  Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Authors:  Sabrina Rizzolio; Gabriella Cagnoni; Chiara Battistini; Stefano Bonelli; Claudio Isella; Jo A Van Ginderachter; René Bernards; Federica Di Nicolantonio; Silvia Giordano; Luca Tamagnone
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

Review 6.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

7.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Authors:  Chang Liu; Maria Chikina; Rahul Deshpande; Ashley V Menk; Ting Wang; Tracy Tabib; Erin A Brunazzi; Kate M Vignali; Ming Sun; Donna B Stolz; Robert A Lafyatis; Wei Chen; Greg M Delgoffe; Creg J Workman; Stacy G Wendell; Dario A A Vignali
Journal:  Immunity       Date:  2019-07-23       Impact factor: 31.745

8.  Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.

Authors:  Sangeeta Goswami; Irina Apostolou; Jan Zhang; Jill Skepner; Swetha Anandhan; Xuejun Zhang; Liangwen Xiong; Patrick Trojer; Ana Aparicio; Sumit K Subudhi; James P Allison; Hao Zhao; Padmanee Sharma
Journal:  J Clin Invest       Date:  2018-07-30       Impact factor: 14.808

9.  Autologous graft versus myeloma: it's not a myth.

Authors:  Shuai Dong; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

10.  T Cell-Specific Adaptor Protein Regulates Mitochondrial Function and CD4+ T Regulatory Cell Activity In Vivo following Transplantation.

Authors:  Johannes Wedel; Maria P Stack; Tatsuichiro Seto; Matthew M Sheehan; Evelyn A Flynn; Isaac E Stillman; Sek Won Kong; Kaifeng Liu; David M Briscoe
Journal:  J Immunol       Date:  2019-09-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.